Selective regional lymphadenectomy: A new conception in the treatment of malignant melanoma;Selektive regionale Lymphadenektomie: Ein neuer ansatz in der primartherapi des malignen melanoms

H+G Zeitschrift fur Hautkrankheiten

Volumn 72, Issue 7, 1997, Pages 492-496

  Koller, J ^a,e   Rettenbacher, L ^b   Gmeiner, D ^c   Dietze, O ^d  

^a Abteilung für Dermatologie   (Germany)

^b Inst Nuklearmed und Endokrinol   (Austria)

^c II Chirurgische Abteilung

^d Inst für Pathologische Anat

^e Salzburger Landeskliniken   (Austria)

Author keywords

Lymph node metastasis; Lymphatic mapping; Malignant melanoma

Indexed keywords

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0030858431     PISSN: 03010481     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. BALCH CH, (1988) The role of elective lymph node dissection in melanoma: rationale, results and controversies, Journal of Clinical Oncology, Vol 6, No 1: 163-172
2. BALCH CH, et al. (1981) A multifactorial analysis of melanoma, Ann. Surg.; Vol 193, No 3: 377-388
3. BALCH CH, et al. (1992) An analysts of prognostic factors in 8500 patients with cutaneous melanoma. Cutaneous Melanoma, 2nd Ed., Balch Ch., Houghton A.N., Milton G.W., Sober A.J., Soong S (Ed), J.B.Lippincott Company, Philadelphia pp 165-187
4. BALCH CH, et al. (1992) Elective lymph node dissection: pros and cons. Cutaneous Melanoma, 2nd Ed., Balch Ch., Houghton A.N., Milton G.W., Sober A.J., Soong S (Ed) J.B.Lippincott Company, Philadelphia pp 345-366
5. BERDEAUX D, et al. (1989) Cutaneous malignant melanoma Cancer 63: 1430-1436
6. CALLERY CH, et al. (1982) Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes Ann.Surg.; Vol 196, No 1: 69-74
7. COCHRAN A, et al. (1988) Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. The American Journal of Surgical Pathology 12 (8): 612-618
8. DAS GUPTA, T.K (1977)Results of treatment of 269 patients with primary cutaneous melanoma. Ann.Surg.; Vol 186, No 2: 201-209
9. DAY C, et al. (1982) Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1,51 - 3.99 mm), Ann.Surg ; Vol 195, No 1: 35-43
10. GLASS F, et al. (1995) The role of selective lymphadenectomy in the management of patients with malignant melanoma, Dermatol.Surg. 21: 979-983
11. KIRKWOOD J.M., et al. (1996) Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. Journal of Clinical Oncology, Vol 14, No 1, 1996: pp 7-17
12. MEYSKENS F, et al. (1988) Cutaneous malignant melanoma (Arizona Cancer Center Experience), Cancer 62: 1207-1214
13. MORTON D, et al. (1992): Mangement of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy, Surgical Oncology Clinics Of North America; Vol 1, No 2: 247-259
14. MORTON D, et al. (1991) Improved long term survival after lymphadenectomy of melanoma metastatic to regional nodes. Ann. Surg.; Vol. 214, No 4: 491-501
15. ROSES D, et al (1985) Prognosis of patients with pathologic stage II cutaneous malignant melanoma, Ann. Surg.; Vol 201, No 1: 103-107
16. WEIDNER F, HORNSTEIN O, (1972) Das Problem der regionalen Lymphknotenmetastasierung beim malignen Melanom, Arch.Derm. Forsch. 245, 50-62